CN1953762B - Gst活化的抗癌化合物在制备改善铂类化合物的抗癌副作用的药物中的用途 - Google Patents

Gst活化的抗癌化合物在制备改善铂类化合物的抗癌副作用的药物中的用途 Download PDF

Info

Publication number
CN1953762B
CN1953762B CN2005800158989A CN200580015898A CN1953762B CN 1953762 B CN1953762 B CN 1953762B CN 2005800158989 A CN2005800158989 A CN 2005800158989A CN 200580015898 A CN200580015898 A CN 200580015898A CN 1953762 B CN1953762 B CN 1953762B
Authority
CN
China
Prior art keywords
anticancer
therapy
gst
activated
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800158989A
Other languages
English (en)
Chinese (zh)
Other versions
CN1953762A (zh
Inventor
盖尔·L·布朗
詹姆斯·G·凯克
迈克尔·M·威克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telik Inc
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc filed Critical Telik Inc
Publication of CN1953762A publication Critical patent/CN1953762A/zh
Application granted granted Critical
Publication of CN1953762B publication Critical patent/CN1953762B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2005800158989A 2004-05-20 2005-05-19 Gst活化的抗癌化合物在制备改善铂类化合物的抗癌副作用的药物中的用途 Expired - Fee Related CN1953762B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57279004P 2004-05-20 2004-05-20
US60/572,790 2004-05-20
PCT/US2005/017960 WO2005112973A1 (en) 2004-05-20 2005-05-19 Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a gst-activated anticancer compound

Publications (2)

Publication Number Publication Date
CN1953762A CN1953762A (zh) 2007-04-25
CN1953762B true CN1953762B (zh) 2012-04-25

Family

ID=34970551

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800158989A Expired - Fee Related CN1953762B (zh) 2004-05-20 2005-05-19 Gst活化的抗癌化合物在制备改善铂类化合物的抗癌副作用的药物中的用途

Country Status (12)

Country Link
US (2) US20050261202A1 (enExample)
EP (1) EP1755632A1 (enExample)
JP (1) JP2007538105A (enExample)
KR (1) KR101174685B1 (enExample)
CN (1) CN1953762B (enExample)
AR (1) AR048971A1 (enExample)
AU (1) AU2005245004B2 (enExample)
BR (1) BRPI0511296A (enExample)
CA (1) CA2566850A1 (enExample)
MX (1) MXPA06013375A (enExample)
TW (1) TW200538149A (enExample)
WO (1) WO2005112973A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
TW200538149A (en) 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
CU23511B6 (es) * 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
ES2293834B1 (es) 2006-07-20 2009-02-16 Consejo Superior Investig. Cientificas Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas.
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
AU2006350707A1 (en) * 2006-11-08 2008-05-15 Chongxi Yu Transdermal delivery systems of peptides and related compounds
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
JP5337143B2 (ja) * 2007-04-14 2013-11-06 サザン リサーチ インスティテュート 化学療法剤と放射線とを併用した新形成の治療方法
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200920347A (en) * 2007-07-16 2009-05-16 Poniard Pharmaceuticals Inc Oral formulations for picoplatin
US8252773B2 (en) * 2007-11-02 2012-08-28 Ziopharm Oncology, Inc. Combination therapy with organic arsenicals
ES2332167B1 (es) 2007-12-04 2010-10-25 Universidad Autonoma De Madrid Empleo de trefoil factor-family 3 (tff3) en el pronostico de sujetos diagnosticados con cancer colorectal.
ES2332557B1 (es) 2007-12-04 2011-02-02 Universidad Autonoma De Madrid Huella genomica para el pronostico de la evolucion de adenocarcinoma colorectal.
JP2011511072A (ja) * 2008-02-08 2011-04-07 ポニアード ファーマシューティカルズ， インコーポレイテッド 結腸直腸癌を治療するためのピコプラチンおよびベバシツマブの使用
CA2717915A1 (en) * 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions
ES2338843B1 (es) 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
EP2169078A1 (en) 2008-09-26 2010-03-31 Fundacion Gaiker Methods and kits for the diagnosis and the staging of colorectal cancer
CN109232716A (zh) 2009-05-08 2019-01-18 上海泰飞尔生化技术有限公司 多肽和多肽相关化合物的高穿透力前药组合物
CN106177963A (zh) * 2009-06-05 2016-12-07 陶制药有限责任公司 用于治疗癌症或癌前病症的交错方法
CN102781316B (zh) 2010-03-01 2016-07-06 陶制药有限责任公司 癌症诊断和成像
US20120251496A1 (en) * 2011-03-31 2012-10-04 Telik, Inc. Ezatiostat for treating multiple myeloma
US20120288554A1 (en) * 2011-05-12 2012-11-15 Telik, Inc. Canfosfamide monotherapy for treating multiple myeloma
WO2013092960A1 (en) 2011-12-22 2013-06-27 Fundacion Gaiker Methods and kits for the diagnosis of colorectal cancer
EP2872161B1 (en) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
JP6727765B2 (ja) 2014-06-17 2020-07-22 日東電工株式会社 アポトーシス誘導剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556942A (en) * 1991-04-29 1996-09-17 Terrapin Technologies, Inc. Glutathione S-transferase-activated compounds
US5767147A (en) * 1995-04-21 1998-06-16 The Regents Of The University Of California Inhibition of glutathione transferase by haloenol lactones
ATE280582T1 (de) 1995-06-07 2004-11-15 Telik Inc Stoffwechseleffekt von bestimmten glutation analogen
US5880097A (en) * 1996-01-04 1999-03-09 Terrapin Techologies, Inc. Tethered prodrugs
US6281223B1 (en) * 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
TW200538149A (en) 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Hua Xu et al..Synergistic cancer cell cytotoxicity of TLK286(TELCYTA TM) in combination with carboplatin, cisplatiin, doxorubicin, docetaxel, paclitaxel or oxaliplatin in human ovarian, lung, breast and colorectal cancer cell lines..《Clinical Cancer Research》.2003,第9卷(第16期), *

Also Published As

Publication number Publication date
MXPA06013375A (es) 2007-03-01
TW200538149A (en) 2005-12-01
WO2005112973A1 (en) 2005-12-01
BRPI0511296A (pt) 2007-12-04
CN1953762A (zh) 2007-04-25
CA2566850A1 (en) 2005-12-01
US20080166428A1 (en) 2008-07-10
EP1755632A1 (en) 2007-02-28
AR048971A1 (es) 2006-06-14
AU2005245004A1 (en) 2005-12-01
AU2005245004B2 (en) 2011-08-04
US8207121B2 (en) 2012-06-26
US20050261202A1 (en) 2005-11-24
KR101174685B1 (ko) 2012-08-16
JP2007538105A (ja) 2007-12-27
KR20070012542A (ko) 2007-01-25

Similar Documents

Publication Publication Date Title
CN1953762B (zh) Gst活化的抗癌化合物在制备改善铂类化合物的抗癌副作用的药物中的用途
CN100508961C (zh) 一种gst活化的抗癌化合物与另一种抗癌疗法的复合药物及制药用途
JP4991107B2 (ja) コンブレタスタチンおよび抗癌剤からなる組成物
JP2006508980A5 (enExample)
JP2015509965A (ja) 併用療法によるプロカスパーゼ３活性化
TW202028182A (zh) 用於癌症治療之免疫調節之組合
US20210023099A1 (en) Combination therapy with a bet inhibitor and a proteasome inhibitor
US20200237779A1 (en) Combination therapy with a bet inhibitor and a bcl-2 inhibitor
Schilder et al. New therapies for ovarian cancer
JP2011500650A (ja) 改良された抗腫瘍治療
TW200835505A (en) 2-{[2-(substituted amion)ethyl]sulfonyl}ethyl N, N, N', N'-tetrakis(2-chloroethyl)phosphorodiamidates
HK40034211A (en) Combination therapy with a bet inhibitor and a proteasome inhibitor
HK1128234A1 (en) Combination comprising combretastatin and anticancer agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120425

Termination date: 20130519